Diagonal Bio AB (publ)

As of September 30, 2025, Diagonal Bio AB (publ) has 1.63B shares outstanding.

As of September 30, 2025, Diagonal Bio AB (publ) maintains a current ratio of 2.05, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended September 30, 2025. Return on assets (ROA) is negative at -32.30, reflecting losses generated across the asset base. Inventory turnover of -0.45 indicates how many times Diagonal Bio AB (publ) sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended September 30, 2025, Diagonal Bio AB (publ) posted a gross margin of 326.96, reflecting its pricing power and cost economics. The operating margin of -3,243.69 and net profit margin of -3,222.87 provide insight into operational efficiency.

Diagonal Bio AB (publ)'s most recent stock split took place on November 25, 2022 with a 103:175 split ratio.

As of September 30, 2025, Diagonal Bio AB (publ) has an Altman Z-Score of -23.30, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.